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Deferriferrichrysin belongs to the siderophore peptide family which are Fe(III)-coordinating cyclic 
peptides. The common structure of this family is three consecutive hydroxamate moieties, such as 
N-acetyl-N-hydroxy-L-ornithine (Aho). We have designed two deferriferrichrysin derivatives 
where three Aho residues were arranged as: cyclo(-Aho-Gly-Aho-Gly-Aho-Gly-) and 
cyclo(-Aho-Ser-Aho-Ser-Aho-Ser-). Comparative evaluation of the physicochemical properties of 
their Fe(III) complexes revealed that naturally occurring deferriferrichrysin formed a more stable 
Fe(III) complex when compared with the two derivatives. This result shows that three consecutive 
Aho residues are indispensable for high affinity Fe(III) binding by deferriferrichrysin. Of note, the 
observed pH-dependent chromogenic response of the Fe(III) complexes of the derivatives suggests 
that these two derivatives should function as sensitive pH indicators in acidic environments. 
 
 




Microbes produce Fe(III) selective chelators, called siderophores,1 to sequester Fe(III), which is 
necessary for cellular redox chemisty,2 but insoluble under physiological conditions. Over 500 
siderophores have been isolated and classified according to coordinate groups and scaffolds. 
Deferriferrichrysin (1) is a cyclic hexapeptide siderophore with three 
N-acetyl-N-hydroxy-L-ornithine (Aho) residues that is produced by Aspergillus oryzae (Figure 
1).3 Its Fe(III) complex, ferrichrysin (2), is a colorant in rice wine (sake). Deferriferrichrome (3)4 
and deferriferrichrome A (4)5 are also hydroxamate-containing cyclic hexapeptides. The common 
feature of this siderophore family is the presence of three consecutive residues with 
Fe(III)-coordinating hydroxamate side-chains. 
These Fe(III)-siderophore complexes are incorporated into the cytoplasm via ABC type 
transporters.1 Using this iron uptake system found in microbes, several siderophore-conjugated 
pharmaceuticals have been designed for a microbe selective drug delivery system.6-8 For example, 
an antibiotic with a triscatecholate siderophore (5) was taken up by Gram-negative bacteria species, 
including Pseudomonas aeruginosa. The mycobactin-artemisinin conjugate (6) was effective 
against drug resistant strains of Mycobacterium tuberculosis, in which Fe(III)-mediated Fenton-type 
radical formation from a mycobactin moiety was also the key active ingredient of this 
anti-tuberculosis conjugate. Thus, Fe(III)-siderophore complexes represent interesting 
pharmaceutical materials for antimicrobial agents. 
In order to investigate the coordinating ability of three consecutive Aho residues in 
deferriferrichrysin (1), we have designed two deferriferrichrysin derivatives, 
cyclo(-Aho-Gly-Aho-Gly-Aho-Gly-) (7a) and cyclo(-Aho-Ser-Aho-Ser-Aho-Ser-) (7b). These two 
compounds contain three Aho residues interspersed by either Gly or Ser residues derived from 
deferriferrichrysin. In this article, we report the synthesis of these two deferriferrichrysin derivatives 




2. Results and discussion 
2.1. Synthesis of deferriferrichrysin derivatives 
In a previous study, we have established a facile synthetic approach to N-Fmoc-protected 
N-acetyl-N-(tert-butoxy)-L-ornithine [Fmoc-Aho(t-Bu)-OH].9 Using this amino acid component 
as a building block in Fmoc-based solid-phase peptide synthesis (SPPS), deferriferrichrysin (1) and 
deferriferrichrome (3) were synthesized.9 According to this protocol, hexapeptide resins 9a,b were 
prepared on 2-chlorotrityl [(2-Cl)Trt] resin (Scheme 1). Peptide elongation was performed by 
standard Fmoc-based SPPS using N,N’-diisopropylcarbodiimide (DIC)/N-hydroxybenzotriazole 
(HOBt). Treatment of the resin with 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) gave t-Bu-protected 
linear peptides 10a,b, which were cyclized using diphenylphosphoryl azide (DPPA)/NaHCO3. 
Linear peptides 10a,b were converted to protected cyclic peptides 11a,b, respectively. In the 
cyclization process of linear peptide 10b, two minor side-products were obtained: an epimeric 
product and a ureal product, which was possibly produced via Curtius rearrangement. These were 
excluded during HPLC purification. Final deprotection of 11a,b provided the expected peptides 
7a,b, respectively.  
 
2.2. Evaluation of Fe(III) coordinating activities of deferriferrichrysin and the derivatives 
Initially, Fe(III) coordinating activities of the siderophore peptides were evaluated by a 
competition experiment using ethylenediaminetetraacetic acid (EDTA).10 After the equimolar 
peptide and Fe(III) were dissolved in phosphate buffer (pH 7.0), the mixture was treated with 
increasing concentrations of EDTA. The proportion of the Fe(III)-peptide complex in the presence 
of EDTA was calculated based on the absorbance intensity at the absorbance maximum of the 
complex (Figure 2). Ferrichrysin (2) formed a stable complex even in the presence of excess EDTA 
[the formation of 83% of the Fe(III)-peptide complex in the presence of three equivalents of EDTA]. 
Forty-seven percent of the Fe(III)-deferriferrichrome (3) complex remained in the presence of three 
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equivalents of EDTA. In contrast, derivatives 7a and 7b were easily deprived of Fe(III) by EDTA 
[22% and 14% of the Fe(III)-peptide complexes remained in the presence of equimolar EDTA]. 
Thus, the order of Fe(III) coordinating activity for the siderophore peptides was deferriferrichrysin 
(1) > deferriferrichrome (3) > cyclo(-Aho-Gly-Aho-Gly-Aho-Gly-) (7a) ≈ 
cyclo(-Aho-Ser-Aho-Ser-Aho-Ser-) (7b) at pH 7.0,11 suggesting that three consecutive Aho residues 
in deferriferrichrysin and naturally occurring siderophore peptides contributed noticeably to the 
high Fe(III) coordinating activity.  
 
2.3. Circular dichroism (CD) spectra of ferrichrysin and the derivatives 
For a hexacoordinate octahedral metal complex of three hydroxamate ligands, there are two 
possible geometric isomers, trans and cis.14,15 Each geometric isomer consists of  and  optical 
isomers.15 All the reported X-ray crystal structures of hexadentate hydroxamate complexes show 
the cis configuration, and the optical chilarities have been determined by CD analysis.16-19 For 
example, it was proven by an X-ray diffraction study that ferrichrome A (4) exists in the cis- 
configuration,20 which was supported by the characteristic 465 nm positive band and the 360 nm 
negative band in the CD spectrum.21 
The Fe(III)-7a complex showed a similar CD spectrum to that of ferrichrysin (2) at pH 7.0 
(Figure 3), which shows that this species predominantly adopts the cis- configuration. In contrast, 
the Fe(III)-7b complex had a positive band at 370 nm and a negative band at 445 nm, indicating 
that this complex predominantly exists in the cis- configuration. Since the 
cyclo(-Xaa-Gly-Xaa-Gly-Xaa-Gly-) scaffold is assumed to exhibit flexible conformations with a 
low number of intramolecular hydrogen bonds,22 the flexibility of peptide 7a may lead to Fe(III) 
complex adopting the usual cis- configuration. In contrast, three side chains of L-Ser in 7b would 
restrict the backbone conformation due to the 1,3-allylic strain-like effect.23 This more rigid 
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conformation of 7b would hinder the usual cis- configuration of Fe(III)-7b complex, resulting in 
the characteristic cis- type coordinating configuration. 
 
2.4. Ultraviolet-visible (UV-vis) absorption spectra of ferrichrysin and the derivatives 
UV-vis spectra of Fe(III)-peptide complexes were acquired in pH-controlled buffers between 1.2 
and 7.0 to reveal the pH-dependent structural changes of the complexes. The UV-vis spectra of 
ferrichrysin (2) were nearly identical (max = 425 nm) over the pH range 1.27.0. Both Fe(III)-7a 
and Fe(III)-7b in pH 5.0 and 7.0 solutions had similar spectra with absorbance max ≈ 425 nm. 
Interestingly, red shifts of the visible max of the spectra of Fe(III)-7a and Fe(III)-7b were observed 
at low pH values (Figure 4). This indicates that symmetric Fe(III) complexes with non-sequential 
Aho residues were easily protonated to change the structure of the complex,24 which is in contrast to 
ferrichrysin. 
The visual appearance of the Fe(III)-peptide complexes in three pH buffers are shown in Figure 
5. A similar orange color was observed between the three ferrichrysin (2) solutions at pH 1.2, 3.6 
and 7.0. In contrast, both solutions of Fe(III)-7a and Fe(III)-7b turned red at low pH. These 
corresponded to the UV-vis spectra of the solutions, suggesting that Fe(III)-7a and Fe(III)-7b 
represent potential pH indicators for acidic solutions.  
 
3. Conclusions 
In this study, we have carried out synthesis and comparative physicochemical analysis of two 
deferriferrichrysin analogs: cyclo(-Aho-Gly-Aho-Gly-Aho-Gly-) (7a) and 
cyclo(-Aho-Ser-Aho-Ser-Aho-Ser-) (7b) containing three interspersed Aho residues to investigate 
the structural basis of ferrichrysin siderophores. The siderophore/EDTA competition experiment 
revealed that the high Fe(III) coordinating activity of naturally occurring siderophore peptides was 
attributable to the three consecutive Aho residues. CD analysis demonstrated that the Fe(III)-7b 
complex exhibited a coordinating configuration not observed in other cyclic hexapeptide 
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siderophores. Notably, characteristic pH-dependent spectral shifts in acidic media were observed 
for the Fe(III)-complexes of peptides 7a and 7b, suggesting that these complexes could be useful as 




4.1.1. General Methods. 1H NMR spectra were recorded using a JEOL ECA-500 spectrometer. 
Chemical shifts are reported in δ (ppm) relative to residual peak as an internal standard. 13C NMR 
spectra were referenced to the CD3CN (in D2O) or residual peak (in DMSO-d6) as an internal 
standard. Exact mass (HRMS) spectra were recorded on a JMS-HX/HX 110A mass spectrometer. 
Optical rotations were measured with a JASCO P-1020 polarimeter. For flash chromatography, 
Wakogel C-300E (Wako) was employed. For analytical HPLC, a COSMOSIL 5C18-ARII column 
(4.6 × 250 mm, Nacalai Tesque Inc., Kyoto, Japan) was employed with a linear gradient of CH3CN 
containing 0.1% (v/v) TFA at a flow rate of 1 mL/min, and eluting products were detected by UV at 
220 nm. Preparative HPLC was performed using a COSMOSIL 5C18-ARII column (20 or 10 × 250 
mm, Nacalai Tesque Inc.) with a linear gradient of CH3CN containing 0.1 % (v/v) TFA at a flow 
rate of 8 or 4 mL/min, respectively. 
 
4.1.2. cyclo(-Aho-Gly-Aho-Gly-Aho-Gly-) (7a). The protected linear peptide resin 9a was 
constructed by Fmoc-based solid-phase synthesis on H-Gly-(2-Cl)Trt resin (0.64 mmol/g, 158 mg, 
0.10 mmol). Fmoc-Gly-OH (0.50 mmol) and Fmoc-Aho(t-Bu)-OH (0.30 mmol) were coupled using 
DIC-HOBt·H2O (equivalent of Fmoc-amino acid) in DMF. Completion of each coupling reaction 
was ascertained using the Kaiser ninhydrin test. The Fmoc-protecting group was removed by 
treating the resin with 20% piperidine in DMF. The resulting protected peptide resin was subjected 
to HFIP–CH2Cl2 (2:8, 20 mL) treatment at room temperature for 2 h. After filtration of the residual 
resin, the filtrate was concentrated under reduced pressure to give a crude linear peptide 10a. To a 
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mixture of the resulting linear peptide in DMF (40 mL), DPPA (53.9 μL, 0.25 mmol) and NaHCO3 
(42.0 mg, 0.50 mmol) were added at –40 °C. The mixture was stirred for 20.5 h with warming to 
room temperature. After filtration, the filtrate was concentrated under reduced pressure, followed by 
flash chromatography over silica gel with CHCl3–MeOH (9:1) to give the crude protected cyclic 
peptide 11a. The crude peptide was treated with CH2Cl2–TFA–thioanisole (10:10:1, 3.65 mL) at 
room temperature for 13 h. The mixture was poured into ice-cold dry Et2O (30 mL). The resulting 
powder was collected by centrifugation and washed three times with ice-cold dry Et2O. The crude 
product was purified by preparative HPLC to afford the title compound as colorless freeze-dried 
powder (13.1 mg, 19% from H-Gly-(2-Cl)Trt resin): [α]27D –11.5 (c 0.82, H2O); 1H-NMR (500 
MHz, D2O) δ: 1.57-1.96 (m, 12H), 2.07-2.18 (m, 9H), 3.56-3.71 (m, 6H), 3.90 (d, J = 16.6 Hz, 3H), 
3.98 (d, J = 16.6 Hz, 3H), 4.35 (dd, J = 6.3, 6.3 Hz, 3H); 13C NMR (125 MHz, D2O) δ: 19.9 (3C), 
22.8 (3C), 28.0 (3C), 43.3 (3C), 47.8 (3C), 54.0 (3C), 171.8 (3C), 174.4 (6C); HRMS (FAB): m/z 
calcd for C27H46N9O12 [M + H]+ 688.3260; found: 688.3258. 
 
4.1.3. cyclo(-Aho(t-Bu)-Ser(t-Bu)-Aho(t-Bu)-Ser(t-Bu)-Aho(t-Bu)-Ser(t-Bu)-) (11b). By the 
identical procedure for the synthesis of peptide 11a and preparative HPLC purification, the 
expected peptide 11b was obtained as white freeze-dried powder (21.6 mg, 19% from 
H-Ser(t-Bu)-(2-Cl)Trt resin): [α]26D –14.0 (c 0.94, MeOH); 1H-NMR (500 MHz, DMSO-d6, 100 °C) 
δ: 1.17 (s, 27H), 1.28 (s, 27H), 1.56-1.81 (m, 12H), 2.02 (s, 9H), 3.50-3.71 (m, 12H), 4.04-4.16 (m, 
6H), 7.62 (d, J = 6.9 Hz, 3H), 7.70 (d, J = 5.7 Hz, 3H); 13C NMR (125 MHz, DMSO-d6, 100 °C) δ: 
20.6 (3C), 22.2 (3C), 26.8 (9C), 26.9 (9C), 28.0 (3C), 48.9 (3C), 53.3 (3C), 54.3 (3C), 60.3 (3C), 
72.7 (3C), 81.6 (3C), 169.0 (3C), 170.5 (3C), 173.5 (3C); HRMS (FAB): m/z calcd for 
C54H100N9O15 [M + H]+ 1114.7333; found: 1114.7334. 
 
4.1.4. cyclo(-Aho-Ser-Aho-Ser-Aho-Ser-) (7b). By the identical procedure for the synthesis of 
peptide 7a, the expected peptide 7b was obtained as light yellow freeze-dried powder (12.3 mg, 
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16% from H-Ser(t-Bu)-(2-Cl)Trt resin): [α]26D –14.9 (c 0.90, H2O); 1H-NMR (500 MHz, D2O) δ: 
1.58-2.04 (m, 12H), 2.06-2.18 (m, 9H), 3.57-3.73 (m, 6H), 3.88 (dd, J = 11.5, 4.6 Hz, 3H), 3.96 (dd, 
J = 11.5, 4.6 Hz, 3H), 4.36 (dd, J = 8.6, 5.2 Hz, 3H), 4.43 (dd, J = 4.6, 4.6 Hz, 3H); 13C NMR (125 
MHz, D2O) δ: 19.8 (3C), 22.9 (3C), 28.1 (3C), 47.8 (3C), 54.5 (3C), 56.8 (3C), 61.3 (3C), 172.0 
(3C), 174.0 (3C), 174.4 (3C); HRMS (FAB): m/z calcd for C30H52N9O15 [M + H]+ 778.3577; found: 
778.3571. 
 
4.2. EDTA/peptide competition experiment 
Peptide and Fe(NO3)3 [18.0 mM in 0.1 mM HNO3] (0.2 mM each) were dissolved in 100 mM 
phosphate buffer (pH 7.0). To this Fe(III)-peptide complex solution, 0.10 to 3.0 equiv of EDTA was 
added. After incubation at 25 °C for 2–3 days, UV-vis spectra were measured. The proportion of the 
Fe(III)-peptide complex was calculated as: [425 nm absorbance of the sample solution]/[425 nm 
absorbance of the control sample (no EDTA)]. 
 
4.3. CD spectra 
CD spectra were recorded on a JASCO J-720 circular dichroism spectrometer at 20 °C. Peptide 
and Fe(NO3)3 [18.0 mM in 0.1 mM HNO3] (0.5 mM each) were dissolved in 100 mM phosphate 
buffer (pH 7.0). 
 
4.4. UV-vis spectra 
UV-vis spectra were recorded on a Shimadzu UV-2450 UV-vis spectrophotometer. Peptide and 
Fe(NO3)3 [18.0 mM in 0.1 mM HNO3] (0.2 mM each) were dissolved in pH-controlled buffers: 50 
mM HCl-KCl buffer (for pH 1.2, 1.6 and 2.0); 50 mM glycine-HCl buffer (for pH 2.4, 2.8, 3.2 and 
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Figure 2. Competition experiments between siderophore peptides and EDTA for Fe(III) 












Figure 5. Appearance of Fe(III)-peptide complex solutions. 
 Peptide and Fe(III) (1.0 mM each) were dissolved in pH-controlled buffers: 50 mM HCl-KCl 


















































Xaa = Gly (8a)
Xaa = Ser(t-Bu) (8b)
Xaa = Gly (9a)
Xaa = Ser(t-Bu) (9b)
Xaa = Gly (11a)
Xaa = Ser(t-Bu) (11b )
H-Aho(t-Bu)-Xaa-Aho(t-Bu)-Xaa-Aho(t-Bu)-Xaa-OH Xaa = Gly (10a)






Scheme 1. Synthesis of deferriferrichrysin derivatives. 
Reagents and conditions: (a) Fmoc-based SPPS; (b) HFIP, CH2Cl2, rt, 2 h; (c) DPPA, NaHCO3, 
DMF, –40 °C to rt; (d) TFA, CH2Cl2, thioanisole, rt (19% from 8a, 16% from 8b); Aho = 
Nδ-acetyl-Nδ-hydroxy-L-ornithine. 
 
